...
首页> 外文期刊>Current Opinion in Oncology >Current advances in the diagnosis and treatment of pancreatic endocrine tumors.
【24h】

Current advances in the diagnosis and treatment of pancreatic endocrine tumors.

机译:胰腺内分泌肿瘤的诊断和治疗的最新进展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE OF REVIEW: A comprehensive literature review of more than 200 original manuscripts published in the last 18 months was conducted to summarize landmark studies performed on the molecular biology, diagnosis, imaging, and treatment of endocrine tumors of the pancreas. RECENT FINDINGS: Recent achievements occurred on many fronts. Identification of a novel insulin splice variant with increased translation efficiency moved forward the understanding of the molecular biology of insulinomas. Results of a 29-year prospective study from the National Institutes of Health clarified the epidemiology of multiple endocrine neoplasia-1 syndrome. Chromogranin A was identified as a promising marker for pancreatic endocrine tumors. New imaging, including F-dopa positron emission tomography and laparoscopic ultrasound, and the effective combination of existing modalities localized and staged tumors with greater accuracy. Nonoperative treatment strategies show promise; discovery of the antiangiogenic properties of octreotide and the overexpression of tyrosine kinase receptors such as c-kit, epidermal growth factor receptor, and platelet-derived growth factor receptor on malignant endocrine pancreatic tumors may lead to promising pharmacologic treatment. SUMMARY: There have been exciting recent advancements in research surrounding endocrine pancreas that hopefully will pave the way for potential improvement in clinical outcomes for patients with these tumors.
机译:综述的目的:对过去18个月中发表的200多种原始手稿进行了全面的文献综述,以总结对胰腺内分泌肿瘤的分子生物学,诊断,影像学和治疗进行的里程碑式研究。最近的发现:最近在许多方面取得了成就。具有提高的翻译效率的新型胰岛素剪接变体的鉴定推动了对胰岛素瘤分子生物学的理解。美国国立卫生研究院进行的一项为期29年的前瞻性研究结果阐明了多发性内分泌瘤1综合征的流行病学。嗜铬粒蛋白A被确定为胰腺内分泌肿瘤的有前途的标志物。新的影像学包括F-多巴正电子发射断层扫描和腹腔镜超声检查,以及现有模式的有效结合,可以更准确地定位和分期肿瘤。非手术治疗策略显示出希望;发现奥曲肽的抗血管生成特性以及酪氨酸激酶受体(例如c-kit,表皮生长因子受体和血小板衍生的生长因子受体)在恶性内分泌胰腺肿瘤上的过度表达可能会导致有希望的药物治疗。摘要:关于内分泌胰腺的研究取得了令人兴奋的最新进展,有望为这些肿瘤患者的临床结局潜在改善铺平道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号